Imaging Biomarkers of Neurodegeneration in Alzheimer’s Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism

Abstract

Background:

Neurodegeneration biomarkers are routinely used in the diagnosis of Alzheimer’s disease (AD).

Objective:

To evaluate the respective contributions of two neuroimaging biomarkers, structural MRI and ¹⁸FDG-PET, in the assessment of neurodegeneration in AD dementia.

Methods:

Patients with mild AD dementia diagnosed based on clinical and cerebrospinal fluid criteria and cognitively healthy subjects, from the Marseille cohort ADAge with cognitive, structural MRI and ¹⁸FDG-PET assessments, were included. Extent of atrophy on MRI and of hypometabolism on ¹⁸FDG-PET were individually evaluated in each patient using a voxel-based analysis on whole-brain approach and compared to healthy subjects. Patients were divided in distinct groups according to their atrophy extent on the one hand and to their hypometabolism extent on the other, then, to their imaging profile combining the extent of the two biomarkers.

Results:

Fifty-two patients were included. The MMSE score was significantly lower in the “Extensive hypometabolism” group than in the “Limited hypometabolism” group (respectively 19.5/30 versus 23/30). A lower Innotest Amyloid Tau Index was associated with an extensive hypometabolism (p = 0.04). There were more patients with low educational level in the “Extensive atrophy” group, while a higher educational level was more found in the “Limited atrophy” group (p = 0.005).

Conclusion:

¹⁸FDG-PET hypometabolism extent is associated with the pathological processes and clinical severity of AD, while MRI atrophy seems to be influenced by the cognitive reserve. In the context of mild AD dementia, these two biomarkers of neurodegeneration are thus not interchangeable and require to be considered in combination rather than in isolation.